We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

RLIP76 in Human Serum in Adults With Rheumatologic Diseases

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00861159
Recruitment Status : Withdrawn (Study withdrawn due to lack of staffing resources and subject interest)
First Posted : March 13, 2009
Last Update Posted : January 12, 2011
Sponsor:
Information provided by:

September 29, 2008
March 13, 2009
January 12, 2011
September 2011
September 2011   (Final data collection date for primary outcome measure)
The focus of the present study is limited to establishing validated protocols for detection of anti-RLIP76 antibodies in human sera. [ Time Frame: three years ]
Same as current
Complete list of historical versions of study NCT00861159 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
RLIP76 in Human Serum in Adults With Rheumatologic Diseases
Measurement Of RLIP76 Auto Antibodies in Human Serum In Adults With Rheumatologic Diseases.
It is the investigators aim to determine the feasibility of directly detecting anti-RLIP76 auto-antibodies in human serum using prepared RLIP76 antigen peptides in persons with rheumatologic disease and persons without rheumatologic diesease ("healthy subjects").
This is an exploratory study conducted to see the feasibility of measuring the anti-RLIP76 antibody and to standardize the methods for its measurement. We will perform these studies on blood samples obtained from human subjects after informed concent for blood draw for research purposes is obtained by the Clinical Research Co-ordinator (CRC).
Observational
Observational Model: Case-Only
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample
The experimental populations subject to study will be 100 outpatients in the rheumatology clinic otherwise undergoing routinely scheduled phlebotomy for standard clinical care purposes.
Carotid Atherosclerosis
Not Provided
1

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Withdrawn
100
September 2011
September 2011   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Adult (age 18+), non-pregnant subjects with previously diagnosed rheumatologic disease will be candidates for the study.

Exclusion Criteria:

  • Children, pregnant women, prisoner, persons with any medical condition that precludes phlebotomy, and patients unwilling or unable to provide consent.
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00861159
2008-31
Yes
Not Provided
Not Provided
Measurement of RLIP76 Auto Antibodies in Human Serum in Adults with Rheumatologic Disease., University of North Texas Health Science Center
University of North Texas Health Science Center
Not Provided
Principal Investigator: Sanjay Awasthi, MD University of North Texas Health Science Center
University of North Texas Health Science Center
January 2011